NEW YORK, NY - October 8, 2013 - LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of BioAmber Inc. (NYSE: BIOA), an industrial biotechnology company that combines advanced fermentation technology and conventional chemistry to manufacture bio-based chemicals. BioAmber is currently building manufacturing capacity for the production of bio-based succinic acid, a building block chemical. The Company has a technology platform that combines industrial biotechnology with chemical catalysis for the conversion of renewable feedstocks into sustainable chemicals. The goal is to replace petroleum-based chemicals with renewable equivalents in a cost-competitive manner.
"BioAmber has all of the pieces in place needed to become a successful commercial scale chemical manufacturer and leader in the green chemical industry," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "They have already demonstrated large scale production of succinic acid at their demonstration plant, and the fully funded plant they are building in Sarnia, Ontario will be mechanically operational by the end of 2014."
BioAmber has a plan in place to produce world-scale quantities of bio-based succinic acid, including collaborations with key industry partners, an experienced management team, and the necessary capital to execute the plan. Experience gained at BioAmber's demonstration plant, believed to be one of the largest bio-based chemical production facilities, is being used to inform the ongoing construction of a new facility in Sarnia, Ontario. The new plant that will be able to produce 30,000 metric tons of bio-SA per year, with potential to increase capacity to 50,000 metric tons. This new facility is fully funded from a combination of sources including BioAmber's partner Mitsui & Co., confirmed government grants and loans, an established loan, and proceeds of the recent IPO. BioAmber already has contracts in place to sell the final product and is also working with partners to find further uses for bio-SA.
In a 50 page Initiation Report by LifeSci Advisors, we explain BioAmber's technology and business plan, including details of the ongoing construction of the commercial scale manufacturing plant in Sarnia, Ontario, the Company's yeast fermentation technology, and efforts to develop new products and markets for succinic acid and its derivatives. We also explore the industry landscape for industrial biotechnology and explain how BioAmber's peers, by failing to perform to expectations, have made investment in the sector difficult. This has, in turn, created a potential opportunity in BioAmber.
Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.
Phone: (646) 597-6979
Phone: 514-844-8000 ext. 120
SOURCE: LifeSci Advisors